BR112022018134A2 - Proteína biespecífica nova e seu uso - Google Patents
Proteína biespecífica nova e seu usoInfo
- Publication number
- BR112022018134A2 BR112022018134A2 BR112022018134A BR112022018134A BR112022018134A2 BR 112022018134 A2 BR112022018134 A2 BR 112022018134A2 BR 112022018134 A BR112022018134 A BR 112022018134A BR 112022018134 A BR112022018134 A BR 112022018134A BR 112022018134 A2 BR112022018134 A2 BR 112022018134A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion protein
- glp
- analogue
- protein
- bispecific
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 7
- 102000037865 fusion proteins Human genes 0.000 abstract 7
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
- 229940121355 glucagon like peptide 2 (glp-2) analogues Drugs 0.000 abstract 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 2
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000006471 dimerization reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 208000037824 growth disorder Diseases 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
PROTEÍNA BIESPECÍFICA NOVA E SEU USO. A presente invenção refere-se a uma proteína de fusão biespecífica nova e um seu uso. Mais especificamente, a presente invenção refere-se a: uma proteína de fusão biespecífica na qual um análogo de GLP-1 e um análogo de GLP-2 são fundidos, ou uma proteína de fusão biespecífica compreendendo uma primeira proteína de fusão na qual um análogo de GLP-1 é ligado a uma região Fc de anticorpo e uma segunda proteína de fusão na qual um análogo de GLP-2 é ligado a uma região FC de anticorpo, em que a proteína de fusão biespecífica é produzida por dimerização da primeira proteína de fusão e da segunda proteína de fusão; e uma composição farmacêutica compreendendo a mesma como um ingrediente ativo, para o tratamento de uma doença ou sintoma que requer crescimento intestinal ou doenças metabólicas como obesidade, diabetes tipo 2 e esteatoepatite não alcoólica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200030727 | 2020-03-12 | ||
| PCT/KR2021/003128 WO2021182928A1 (ko) | 2020-03-12 | 2021-03-12 | 신규 이중 특이성 단백질 및 그의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022018134A2 true BR112022018134A2 (pt) | 2022-11-22 |
Family
ID=77670796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022018134A BR112022018134A2 (pt) | 2020-03-12 | 2021-03-12 | Proteína biespecífica nova e seu uso |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4119571A4 (pt) |
| KR (2) | KR102349718B1 (pt) |
| CN (1) | CN115485292A (pt) |
| BR (1) | BR112022018134A2 (pt) |
| WO (1) | WO2021182928A1 (pt) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4220386B2 (ja) | 2001-10-09 | 2009-02-04 | エナジー リレーテッド デバイシーズ インク | 膜を使用する触媒ヒーター |
| EP1771066A2 (en) * | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
| ES2397289T3 (es) * | 2005-09-22 | 2013-03-06 | Biocompatibles Uk Ltd. | Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada |
| EP2662449B1 (en) | 2007-05-30 | 2017-02-15 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
| SI2393828T1 (sl) | 2009-02-03 | 2017-01-31 | Amunix Operating Inc. | Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo |
| EA021146B1 (ru) * | 2009-03-27 | 2015-04-30 | Глаксо Груп Лимитед | Продукты слияния и конъюгаты лекарственных средств |
| KR101825048B1 (ko) * | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
| EP3526241A1 (en) * | 2016-10-14 | 2019-08-21 | Xencor, Inc. | Il15/il15r heterodimeric fc-fusion proteins |
| CA3140561A1 (en) * | 2019-05-14 | 2020-11-19 | Progen Co., Ltd. | A novel modified immunoglobulin fc fusion protein and use thereof |
-
2021
- 2021-03-12 EP EP21767580.0A patent/EP4119571A4/en active Pending
- 2021-03-12 WO PCT/KR2021/003128 patent/WO2021182928A1/ko unknown
- 2021-03-12 KR KR1020210032692A patent/KR102349718B1/ko active IP Right Grant
- 2021-03-12 CN CN202180034304.8A patent/CN115485292A/zh active Pending
- 2021-03-12 BR BR112022018134A patent/BR112022018134A2/pt unknown
-
2022
- 2022-01-05 KR KR1020220001674A patent/KR20220005622A/ko active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| KR102349718B1 (ko) | 2022-01-11 |
| EP4119571A1 (en) | 2023-01-18 |
| KR20220005622A (ko) | 2022-01-13 |
| CN115485292A (zh) | 2022-12-16 |
| EP4119571A4 (en) | 2024-04-03 |
| KR20210116322A (ko) | 2021-09-27 |
| WO2021182928A1 (ko) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022014271A2 (es) | Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo | |
| BR112018008805A2 (pt) | proteínas de função dupla e composição farmacêutica que compreende a mesma | |
| BR112021019256A2 (pt) | Moduladores de receptor x4 de proteína g relacionado a mas e produtos e métodos relacionados | |
| AU2012338731B2 (en) | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition | |
| Redwan | Animal-derived pharmaceutical proteins | |
| CN106132442A (zh) | 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途 | |
| ES2687651T3 (es) | Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos | |
| BR112022015979A2 (pt) | Vetores de terapia genética para tratamento de doenças cardíacas | |
| Malkesman et al. | Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants | |
| BR112022020643A2 (pt) | Método de tratamento de esteato-hepatite não alcoólica | |
| BR112021023153A2 (pt) | Compostos de pirazol dissubstituídos como inibidores de ceto-hexoquinase | |
| BR112022018134A2 (pt) | Proteína biespecífica nova e seu uso | |
| BR112021025394A2 (pt) | Derivados de antraciclina, conjugados de fármaco e molécula de ligação ao alvo, uso de conjugado de fármaco e molécula de ligação ao alvo, método de tratamento de uma doença em um paciente em necessidade de tratamento, e composição farmacêutica | |
| BR112022022024A2 (pt) | Uso de um componente (i) em combinação com um componente (ii), composição farmacêutica, medicamento composto e kit | |
| BR112023000747A2 (pt) | Composições para o tratamento de obesidade | |
| BR112020004935A8 (pt) | Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular | |
| BR112022023722A2 (pt) | Processo para preparar um agonista dual de glp-1/glucagon | |
| BR112022025334A2 (pt) | Derivado de insulina degludeca, método de preparação do mesmo, e uso do mesmo | |
| BR112021009912A2 (pt) | Proteína de ligação a alfa receptor de folato, composição, e, método para produção da proteína de ligação a folr1 | |
| Hassan et al. | A vitamin DC/D ring-derived compound with cytotoxicity | |
| BR112022027124A2 (pt) | Formulações para promover a hidratação e métodos de uso das mesmas | |
| BR112022026999A2 (pt) | Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas | |
| PE20080674A1 (es) | Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico | |
| BR112023025305A2 (pt) | Composições farmacêuticas, proteína de fusão, e, uso do inibidor do membro 19 da família 4 l seis da transmembrana | |
| Maekawa et al. | Syntheses of 25-Adamantyl-25-alkyl-2-methylidene-1α, 25-dihydroxyvitamin D3 Derivatives with Structure–Function Studies of Antagonistic and Agonistic Active Vitamin D Analogs |